View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures

Novo Nordisk A/S: Annual update

Our credit view of this issuer reflects A degree of M&A risk.

Novo Nordisk A/S: Annual update

Our credit view of this issuer reflects A degree of M&A risk.

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Martial Descoutures
  • Martial Descoutures
Martial Descoutures
  • Martial Descoutures

Novo Nordisk A/S: Annual update

Our credit view of this issuer reflects A degree of M&A risk.

Novo Nordisk A/S: Sales and EBITDA correction will widen in 2026, a cr...

Weaker 2026 outlook will pressure cash flow and slightly increase leverage

AstraZeneca PLC: Collaboration with CSPC strengthens weight-management...

AstraZeneca will pay $1.2 billion upfront, with up to $3.5 billion in milestones. The deal broadens its position in the obesity-care market with little immediate effect on its credit quality

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch